OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
NCT00041535
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
NIH
Sponsor class
Conditions
Gaucher Disease
Interventions
DRUG:
OGT 918
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)